RxDoctor Payments DataLook up a doctor →

Robert Baer, MD

Dermatology · Suffolk, VANPI 1083720767

Payments from drug & device makers

$302,505in general payments, 2019–2025

Across 1,018 payments — averaging $297.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$106K
  • Regeneron Healthcare Solutions, Inc.$82K
  • Sanofi$63K
  • Dermavant Sciences, Inc.$17K
  • Amgen$10K
  • Novartis$7K
  • plus $18K from 31 others

What the payments were for

  • Consulting fees$2,6481%
  • Speaking & faculty fees$275,06891%
  • Travel & lodging$3,0291%
  • Food & beverage$20,9927%
  • Education$7680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$302,505 in reported general payments places this provider in the 95th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia

Medicare billing

Part B allowed, 2024
$510,375
Medicare patients
1,980
Services billed
5,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab28$300,150
Dupixent SyringeDupilumab71$266,179
Dupixent PenDupilumab61$229,602
Enbrel SureclickEtanercept15$164,376
OtezlaApremilast33$147,687
EnbrelEtanercept13$94,448
Cosentyx Sensoready (2 Pens)Secukinumab12$91,575
Fluorouracil108$7,897
Tacrolimus30$5,096
Ketoconazole197$4,407
Calcipotriene29$3,256
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc107$3,246
Clobetasol Propionate36$3,034
Doxycycline Monohydrate111$2,349
Triamcinolone Acetonide265$2,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$9,848$242,13446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 dermatology providers in Virginia.

Other dermatology in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →